Communiqués Sutro Biopharma, Inc.

Actions

STRO

US8693672011

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 19:22:32 13/08/2026			Varia. 5j.	Varia. 1 janv.
21,58 ^USD	+1,31%		-10,39%	+87,04%

12/08	Sutro Biopharma, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
28/05	Sutro Biopharma, Inc. : Barclays relève sa recommandation à acheter	ZM

Communiqués

12/08	Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study	AQ
14/05	Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights	AQ
20/04	Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026	AQ
23/03	Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights	AQ
25/02	Sutro Biopharma to Participate in Upcoming Investor Conferences	AQ
23/02	Sutro Biopharma Announces Participation at the 16th World ADC London Summit	AQ
10/02	Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering	AQ
07/01	Sutro Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference	AQ
19/12	Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines	AQ
17/12	Sutro Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement	AQ
16/12	Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
03/12	Sutro Biopharma Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in TF-Expressing Solid Tumors	AQ
01/12	Sutro Biopharma Announces 1-for-10 Reverse Stock Split	AQ
12/11	Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&D Day	AQ
06/11	Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights	AQ
05/11	Sutro Biopharma to Host Virtual Research & Development Day on November 12, 2025	AQ
03/11	Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference	AQ
29/09/25	Sutro Biopharma : Announces Operational Restructuring Intended to Extend Cash Runway through Key Milestones	PU
07/08/25	Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights	AQ
22/07/25	Sutro Biopharma Announces Research Collaboration with the FDA to Advance Regulatory Standards for Antibody Drug Conjugates	AQ
02/06/25	Sutro Biopharma Appoints Greg Chow as Chief Financial Officer	AQ
08/05/25	Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights	AQ
01/05/25	Sutro Biopharma to Participate in Upcoming Investor Conferences	AQ
28/04/25	Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025	AQ
17/03/25	Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRaME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025	AQ